7-bromo-4-chloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine | 1255939-58-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: 7-bromo-4-chloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine
• 英文别名: 7-bromo-4-chloro-5-methylpyrrolo[3,2-d]pyrimidine
• CAS: 1255939-58-2
• 化学式: C₇H₅BrClN₃
• 分子量: 246.494
• InChiKey: HCTVKWPEVANMLG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7-bromo-4-chloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 90.0~120.0 ℃ 、1.5 MPa 条件下， 反应 21.0h， 生成 methyl 4-((2,4-dimethoxybenzyl)amino)-5-methyl-5H-pyrrolo[3,2-d]pyrimidin-7-carboxylate
  参考文献：
  名称：

  [EN] ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF
  [FR] COMPOSÉ ARYLAMIDE, COMPOSITION PHARMACEUTIQUE LE COMPRENANT, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
  [ZH] 芳基酰胺化合物、包含其的药物组合物及其制备方法和用途

  摘要：

  本发明涉及式（I'）的芳基酰胺化合物、包含其的药物组合物、其制备方法及其用于预防或治疗肿瘤相关的疾病或病况。

  公开号：

  WO2022089219A1
• 作为产物：
  描述：

  4-氯-5-甲基-5H-吡咯并[3,2-d]嘧啶 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 二氯甲烷 为溶剂， 以76%的产率得到7-bromo-4-chloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine
  参考文献：
  名称：

  Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring

  摘要：

  Purine analogs modified in the five-membered ring have been synthesized and examined for antibacterial activity against Mycobacterium tuberculosis H(37)Rv in vitro employing the microplate alamar blue assay (MABA). The 9-deaza analogs were only found to be weak inhibitors, but the 8-aza-, 7-deaza- and 8-aza-7-deazapurine analogs studied displayed excellent antimycobacterial activities, some even substantially better than the parent purine. In the 7-deazapurine series, MIC values between 0.08 and 0.35 mu M, values comparable or better than the reference drugs used in the study (MIC rifampicin 0.09 mu M, MIC isoniazid 0.28 mu M and MIC PA-824 0.44 mu M). The five most active compounds were also examined against a panel of drug-resistant Mtb strain, and they all retained their activity. The compounds examined were significantly less active against M. tuberculosis in a state of non-replicating persistence (NRP). MIC in the low-oxygen-recovery assay (LORA) >= 60 mu M. The 7-deazapurines were somewhat more toxic towards mammalian cells, but still the selectivity indexes were excellent. The non-purine analogs exhibit a selective antimycobacterial activity. They were essentially inactive against Staphylococcus aureus and Escherichia coli. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.08.016

文献信息

• NOVEL PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING SAME AS AN ACTIVE INGREDIENT
  申请人：Hanmi Pharmaceutical Co., Ltd.

  公开号：EP2738174A2

  公开（公告）日：2014-06-04

  The present invention relates to a compound represented by formula (I) for inhibiting the activity of diacylglycerol O-acyltransferase type 1 (DGAT1), and pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising same as an active ingredient. The compound of the present invention may be used effectively in the treatment or prevention of a disease or condition mediated by the activity of DGAT1 such as obesity, type II diabetes, dyslipidemia, metabolic syndrome, and the like, without any adverse effects: wherein A, B, X, and R5 to R7 are the same as defined in the specification.

  本发明涉及一种化合物，其由式(I)表示，用于抑制二酰基甘油酰基转移酶1型（DGAT1）的活性，以及其药学上可接受的盐，以及包含其作为活性成分的药物组合物。本发明的化合物可以有效用于治疗或预防由DGAT1活性介导的疾病或病况，如肥胖、2型糖尿病、血脂异常、代谢综合征等，而不产生任何不良影响： 其中A、B、X和R5到R7与规范中定义的相同。
• NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS
  申请人：Son Jung Beom

  公开号：US20130274268A1

  公开（公告）日：2013-10-17

  The present invention relates to a bicyclic compound for modulating G protein-coupled receptors. The inventive compound provides preventing or treating a disease associated with the modulation of G protein-coupled receptors, particularly GPR119 G protein-coupled receptors.

  本发明涉及一种用于调节G蛋白偶联受体的双环化合物。该创新化合物可用于预防或治疗与调节G蛋白偶联受体相关的疾病，特别是GPR119 G蛋白偶联受体。
• [EN] BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS HÉTÉROCYCLES BICYCLIQUES ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：MERCK SHARP & DOHME

  公开号：WO2011159657A1

  公开（公告）日：2011-12-22

  Compounds of structural formula I: are GPR119 agonists and are useful for the treatment, control or prevention of disorders responsive to agonism of GPR119, such as metabolic-related disorders such as type I diabetes, type II diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia or syndrome X. The compounds are also reported as being useful for controlling weight gain, controlling food intake, and inducing satiety in mammals.

  结构式I的化合物：是GPR119激动剂，用于治疗、控制或预防对GPR119激动有响应的疾病，如代谢相关疾病，如1型糖尿病、2型糖尿病、葡萄糖耐量不足、胰岛素抵抗、高血糖、高脂血症、高三酰甘油血症、高胆固醇血症、血脂异常或X综合征。这些化合物还被报道为在哺乳动物中控制体重增加、控制食物摄入和诱导饱腹感方面有用。
• Bicyclic compound for modulating G protein-coupled receptors
  申请人：Son Jung Beom

  公开号：US08853213B2

  公开（公告）日：2014-10-07

  The present invention relates to a bicyclic compound for modulating G protein-coupled receptors. The inventive compound provides preventing or treating a disease associated with the modulation of G protein-coupled receptors, particularly GPR119 G protein-coupled receptors.

  本发明涉及一种用于调节G蛋白偶联受体的双环化合物。该发明化合物提供了预防或治疗与调节G蛋白偶联受体有关的疾病，特别是GPR119 G蛋白偶联受体的疾病。
• WO2019180683A5
  申请人：——

  公开号：WO2019180683A5

  公开（公告）日：2022-03-29